Lian Zhang

Dr. Lian Zhang


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in American Journal of Roentgenology
Verified
Journal Article
Closed access
Franco OrsiFranco Orsi
Franco Orsi
LZLian Zhang
Lian Zhang
PAPaolo Arnone
Paolo Arnone
GOGianluigi Orgera
Gianluigi Orgera
GBGuido Bonomo
Guido Bonomo
UVUmberto Veronesi
Umberto Veronesi
OBJECTIVE. The aim of this study was to evaluate the safety and efficacy of ultrasound-guided high-intensity focused ultrasound therapeutic ablation of solid tumors in difficult locations.SUBJECTS AND METHODS. A procedure was performed with a focused ultrasound tumor therapeutic system which provides real-time ultrasound guidance. All patients underwent MDCT or MRI, and some patients underwent PET/CT. From November 2007 through April 2009, 31 patients with 38 lesions of the liver and pancreas in difficult locations were treated. Six patients had hepatocellular carcinoma, 13 patients had hepatic metastasis from colorectal cancer, two had hepatic metastases of breast cancer, two had hepatic metastasis of neuroendocrine tumors, one patient had lymph node metastasis of breast cancer at the hepatic hilum, six patients had pancreatic cancer, and one patient had a neuroendocrine tumor. Difficult location was defined as tumor adjacent to a main blood vessel, the heart, the gallbladder and bile ducts, the bowel, o...

1 August 2013 in Journal of Therapeutic Ultrasound
Verified
Journal Article
Open access
PDF file
JAJF Aubry
JF Aubry
KPKim Butts Pauly
Kim Butts Pauly
CMChrit Moonen
Chrit Moonen
Gail ter HaarGail ter Haar
Gail ter Haar
MRMario Ries
Mario Ries
WGWladyslaw M Gedroyc
Wladyslaw M Gedroyc
Clinical use of high-intensity focused ultrasound (HIFU) under ultrasound or MR guidance as a non-invasive method for treating tumors is rapidly increasing. Tens of thousands of patients have been treated for uterine fibroid, benign prostate hyperplasia, bone metastases, or prostate cancer. Despite the methods' clinical potential, the liver is a particularly challenging organ for HIFU treatment due to the combined effect of respiratory-induced liver motion, partial blocking by the rib cage, and high perfusion/flow. Several technical and clinical solutions have been developed by various groups during the past 15 years to compensate for these problems. A review of current unmet clinical needs is given here, as well as a consensus from a panel of experts about technical and clinical requirements for upcoming pilot and pivotal studies in order to accelerate the development and adoption of focused ultrasound for the treatment of primary and secondary liver cancer.

1 November 2015 in Ultrasonics Sonochemistry
Verified
Journal Article
Closed access
LSLian Shui
Lian Shui
SMShihua Mao
Shihua Mao
QWQingrong Wu
Qingrong Wu
GHGuohua Huang
Guohua Huang
JWJian Wang
Jian Wang
LZLian Zhang
Lian Zhang

4 December 2013 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
XZXin Zhang
Xin Zhang
KLKequan Li
Kequan Li
BXBin Xie
Bin Xie
MHMin He
Min He
JHJia He
Jia He
LZLian Zhang
Lian Zhang

24 May 2018 in International Journal of Hyperthermia
Verified
Journal Article
Open access
YLYunchang Liu
Yunchang Liu
WZWendy Wenyi Zhang
Wendy Wenyi Zhang
MHMin He
Min He
CGChunmei Gong
Chunmei Gong
BXBin Xie
Bin Xie
LZLian Zhang
Lian Zhang
Objective: To retrospectively analyze the adverse effects of high-intensity focused ultrasound (HIFU) in management of benign uterine diseases. Materials and methods: From 2011 to 2017, 27,053 patients with benign uterine diseases were treated with HIFU in 19 centers in China. Among them, 17,402 patients had uterine fibroids, 8434 had adenomyosis, 876 had caesarean scar pregnancies, and 341 had placenta accreta. Results: The median age, height, weight, BMI of the patients was 42 years, 158 mm, 56 kg, 22.5 kg/cm2, respectively. After HIFU treatment, 13,170 adverse events were observed. Based on society of interventional radiology classification system, these adverse events were classified as Class A (47.5030%), Class B (0.7947%), Class C (0.3327%), and Class D (0.0518%). The rate of major adverse effects (Class C&D) was 0.3844%. Major adverse effects include skin burn, leg pain, vaginal discharge or bleeding, urinary retention, acute cystitis, intrauterine infection, bowel injury, acute renal failure, deep vein thrombosis, pubic symphysis injury, post-HIFU thrombocytopenia, sciatic nerve injury, and hydronephrosis. In 2011, the annual rate of major adverse effects was 0.9565%; the incidence decreased to 0.2852% in 2017. No significant difference was observed in the rates of major adverse effects between patients with uterine fibroids, adenomyosis and placenta accreta. Conclusions: Based on the results with low rate of major adverse effects from multiple centers, we concluded that HIFU is safe in treating patients with benign uterine diseases. With development of this technique and more experience on the part of the physicians, the rates of the major adverse effects will be further lowered.

22 March 2016 in International Journal of Hyperthermia
Verified
Journal Article
Closed access
PDF file
CGChunmei Gong
Chunmei Gong
BYBin Yang
Bin Yang
YSYarong Shi
Yarong Shi
ZLZhongqiong Liu
Zhongqiong Liu
LWLili Wan
Lili Wan
LZLian Zhang
Lian Zhang
Objectives The aim of this study was to investigate factors affecting ablative efficiency of high intensity focused ultrasound (HIFU) for adenomyosis. Materials and methods In all, 245 patients with adenomyosis who underwent ultrasound guided HIFU (USgHIFU) were retrospectively reviewed. All patients underwent dynamic contrast-enhanced magnetic resonance imaging (MRI) before and after HIFU treatment. The non-perfused volume (NPV) ratio, energy efficiency factor (EEF) and greyscale change were set as dependent variables, while the factors possibly affecting ablation efficiency were set as independent variables. These variables were used to build multiple regression models. Results A total of 245 patients with adenomyosis successfully completed HIFU treatment. Enhancement type on T1 weighted image (WI), abdominal wall thickness, volume of adenomyotic lesion, the number of hyperintense points, location of the uterus, and location of adenomyosis all had a linear relationship with the NPV ratio. Distance from skin to the adenomyotic lesion’s ventral side, enhancement type on T1WI, volume of adenomyotic lesion, abdominal wall thickness, and signal intensity on T2WI all had a linear relationship with EEF. Location of the uterus and abdominal wall thickness also both had a linear relationship with greyscale change. Conclusion The enhancement type on T1WI, signal intensity on T2WI, volume of adenomyosis, location of the uterus and adenomyosis, number of hyperintense points, abdominal wall thickness, and distance from the skin to the adenomyotic lesion’s ventral side can all be used as predictors of HIFU for adenomyosis.